Trial Profile
A Phase 1 Randomized, Single-Center, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC-1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs RVSV-S-GP/VP40 vaccine (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme; New Links Genetics Corporation
- 09 Feb 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 09 Feb 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 01 Apr 2015 Results published in the New England Journal of Medicine, according to a Public Health Agency of Canada media release.